Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 30, 2015, 34 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.00 to $87,499,988.94.

Highlighted Stocks Traded by Insiders:

Mannatech (MTEX) - FREE Research Report

Robbins Marlin Ray, who is Director at Mannatech, bought 5,000 shares at $18.98 on March 30, 2015. Following this transaction, the Director owned 65,000 shares meaning that the stake was boosted by 8.33% with the 5,000-share transaction.

The shares most recently traded at $18.07, down $0.91, or 5.04% since the insider transaction. Historical insider transactions for Mannatech go as follows:

  • 4-Week # shares bought: 1,900
  • 4-Week # shares sold: 1,200
  • 12-Week # shares bought: 1,900
  • 12-Week # shares sold: 1,200
  • 24-Week # shares bought: 1,900
  • 24-Week # shares sold: 1,200

The average volume for Mannatech has been 19,600 shares per day over the past 30 days. Mannatech has a market cap of $51.1 million and is part of the consumer goods sector and consumer non-durables industry. Shares are down 30.92% year-to-date as of the close of trading on Monday.

Mannatech, Incorporated develops and sells health products. Its health products include nutritional supplements, health solutions for children, and additional nutrients. The company also offers weight and fitness products; and topical, skin care, and anti-aging products. The company has a P/E ratio of 8.0. Currently, there are no analysts who rate Mannatech a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MTEX - FREE

TheStreet Quant Ratings rates Mannatech as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, expanding profit margins, increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Mannatech Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Flanigan's (BDL) - FREE Research Report

Kastner Jeffrey D, who is CFO & Secretary at Flanigan's, sold 4,705 shares at $32.27 on March 30, 2015. Following this transaction, the CFO & Secretary owned 5,295 shares meaning that the stake was reduced by 47.05% with the 4,705-share transaction.

The shares most recently traded at $32.01, down $0.26, or 0.82% since the insider transaction. Historical insider transactions for Flanigan's go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 10,323
  • 24-Week # shares sold: 10,323

The average volume for Flanigan's has been 11,300 shares per day over the past 30 days. Flanigan's has a market cap of $59.8 million and is part of the services sector and leisure industry. Shares are up 5.3% year-to-date as of the close of trading on Friday.

Flanigan's Enterprises, Inc. operates a chain of full-service restaurants and package liquor stores in South Florida. The stock currently has a dividend yield of 0.47%. The company has a P/E ratio of 20.4.

Exclusive Offer: Get the latest Stock Analysis on BDL - FREE

TheStreet Quant Ratings rates Flanigan's as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Flanigan's Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen (BIIB) - FREE Research Report

Sandrock Alfred, who is Grp SVP, Chief Medical Officer at Biogen, sold 430 shares at $430.12 on March 30, 2015. Following this transaction, the Grp SVP, Chief Medical Officer owned 8,574 shares meaning that the stake was reduced by 4.78% with the 430-share transaction.

The shares most recently traded at $429.11, down $1.01, or 0.24% since the insider transaction. Historical insider transactions for Biogen go as follows:

  • 4-Week # shares sold: 8,284
  • 12-Week # shares sold: 19,035
  • 24-Week # shares sold: 26,083

The average volume for Biogen has been 1.9 million shares per day over the past 30 days. Biogen has a market cap of $100.9 billion and is part of the health care sector and drugs industry. Shares are up 27.15% year-to-date as of the close of trading on Monday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. The company has a P/E ratio of 34.8. Currently, there are 11 analysts who rate Biogen a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null